TCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TScan Therapeutics Inc (TCRX) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the company has shown significant revenue growth and hedge funds are buying, the financial performance remains weak with a substantial net income loss and declining EPS. Additionally, there are no strong technical or proprietary trading signals to support an immediate buy decision.
The MACD is positive and expanding, which is a bullish signal. RSI is neutral at 63.615, indicating no overbought or oversold conditions. Moving averages are converging, suggesting a lack of a clear trend. Key support and resistance levels are at S1: 1.009 and R1: 1.127, with the pre-market price at 1.099, close to the resistance level.
Wedbush raised the price target to $5 and maintained an Outperform rating, citing upcoming trial results and updates.
No recent news or congress trading data to act as a sentiment driver. The stock has a 90% chance to decline by -0.32% in the next day and minimal short-term upside potential.
In Q4 2025, revenue increased significantly by 286.02% YoY to $2,567,000. However, net income dropped to -$22,977,000 (-35.83% YoY), and EPS fell to -0.18 (-40.00% YoY). Gross margin remained flat at 100%.
Wedbush raised the price target from $4 to $5 and maintained an Outperform rating. The firm highlighted upcoming trial results and updates as potential catalysts for the stock.
